Event Brief
May 13, 2026 at 6:04 AM ET
Health panel approves iPS cell-derived Parkinson’s treatment
By The BriefBrief
A health panel approved Sumitomo Pharma’s Amchepry, making it the first commercial iPS-derived product.
WHO: Sumitomo Pharma
WHAT: Health panel approval of Amchepry for Parkinson’s disease
WHEN: May 13, 2026 at 5:00 AM ET
WHERE: Japan
WHY: Part of a scheduled process.
Reporting from 1 identified publisher for this event.
View all 1 publishers
Publishers represented across this event arc
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Companies turn sargassum into sustainable products
Mexico
May 13, 2026 at 6:06 AM ET
OECD says BOJ policy rate could reach 2% by end-2027
Oecd
May 13, 2026 at 6:04 AM ET
Nissan expects return to profit after huge loss
Nissan
May 13, 2026 at 6:04 AM ET
Border Police seize 10,000 cannabis plants in 18 greenhouses
Israel
May 13, 2026 at 6:04 AM ET
Page 19068 of 21441
Same format. Every time.
Continue reading — sign in or create a free account with
